Sepsis pp 90-100 | Cite as

AIDS in the Intensive Care Unit

  • Guillermo Ortiz-Ruiz
  • Carlos Alvarez


Patients infected with the human immunodeficiency virus (HIV) are at risk of acquiring a great variety of critical illnesses because of progressive immunodeficiency and the multiple exposures to medications they are receiving. Notwithstanding the great availability of prophylactic effective treatments, Pneumocystis carinii (recently called Pneumocystis jiroveci) continues to be an important cause for pneumonia and respiratory failure, requiring admission to the ICU with a significant risk of increased mortality. Bacterial sepsis is another reason for managing this group of patients at the ICU. This imposes a challenge for critical care personnel because of the worse prognosis observed in this population. On the other hand, the effective use of combined antiretroviral therapy [highly active antiretroviral therapy (HAART)] has reduced the high incidence of opportunistic infections and has drastically improved long-term survival in patients infected with HIV.2 Nevertheless, the use of these agents could be associated with severe adverse effects (e.g., pancreatitis, hepatic steatosis, and lactic acidosis syndrome), which in a great many cases require management in the ICU.


Human Immunodeficiency Virus Acute Pancreatitis Hepatic Steatosis Lactic Acidosis Pneumocystis Carinii Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nickas G, Wachter RM. Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med 2000; 160: 541–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Bartlett JG, Gallant JE. Antiretroviral therapy. In: Bartlett JG, Gallant JE, eds. 2001–2002 Medical management of HIV infection. Baltimore: Johns Hopkins University, Division of Infectious Diseases, 2001: 39–97.Google Scholar
  3. 3.
    De Palo VA, Millstein BH, Mayo PH, et al. Outcome of intensive care in patients with HIV infection. Chest 1995; 107: 506–10.PubMedCrossRefGoogle Scholar
  4. 4.
    Lazard T, Retel O, Guidet B, et al. AIDS in a medical intensive care unit: immediate prognosis and long-term survival. JAMA 1996; 276: 1240–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Rosen MJ, Clayton K, Schneider RF, et al. Intensive care of patients with HIV infection: Utilization, critical illnesses, and outcomes. Am J Respir Crit Care Med 1997; 155: 67–71.PubMedGoogle Scholar
  6. 6.
    Casalino E, Mendoza-Sassi G, Wolff M, et al. Predictors of short and long-term survival in HIV-infected patients admitted to the ICU. Chest 1998; 113: 421–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Bonarek M, Morlat P, Chene G, et al. Prognostic score of short-term survival in HIV-infected patients admitted to medical intensive care units. Int J STD AIDS 2001; 12: 239–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Rosen MJ. Intensive care of patients with HIV infection. Semin Respir Infect 1999; 14: 366–71.PubMedGoogle Scholar
  9. 9.
    Leifeld L, Rockstroh J, Skaide S, et al. Indication, outcome and follow-up of intensive care in patients with HIV-infection. Eur J Med Res 2000; 5: 199–202.PubMedGoogle Scholar
  10. 10.
    Reddy R, Daftary M. Predictors of outcomes in HIV-positive ICU patients. IDSA, Chicago, IL, 2002, abstract 537.Google Scholar
  11. 11.
    Curtis JR. ICU outcomes for patients with HIV infection: a moving target. Chest 1998; 113: 269–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Morris A, Wachter RM, Luce J, et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17: 73–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Morris A, Creasman J, Turner J, et al. Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002; 166: 262–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Reddy R, Daftary M. Outcomes of using antiretrovirals in critically ill HIV infected patients in the ICU setting. IDSA, Chicago, IL, 2002, abstract 539.Google Scholar
  15. 15.
    Meyer CN, Skinhoj P, Prag J. Bacteremia in HIV positive and AIDS patients: incidence, species distribution, risk-factors, outcome, and influence of long-term prophylactic antibiotic treatment. Scand J Infect Dis 1994; 26: 635–42.PubMedCrossRefGoogle Scholar
  16. 16.
    Northfelt DW, Polsky B. Bacteremia in persons with HIV infection. AIDS Clin Rev 1991; 59–79.Google Scholar
  17. 17.
    Brettle RP. Bacterial infections in HIV: the extent and nature of the problem. Int J STD AIDS 1997; 8: 5–15.PubMedCrossRefGoogle Scholar
  18. 18.
    Rosenberg AL, Seneff MG, Atiyeh L, et al. The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: Implications for future care in the age of increasing antiretroviral resistance. Crit Care Med 2001; 29: 548–56.PubMedCrossRefGoogle Scholar
  19. 19.
    Manfredi R, Nanetti A, Ferri M, et al. HIV associated non-mycobacterial sepsisbacteremia, before and during the highly active antiretoviral therapy era. AIDS 1999; 13: 1274–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Thyrault M, Gachot B, Chastang C, et al. Septic shock in patients with the acquired immunodeficiency syndrome. Intensive Care Med 1997; 23: 1018–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Vidal F, Mensa J, Maritnex JA, et al. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 1999; 18: 473–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Da Silva B, Singer W, Fong IW, et al. In vivo cytokine and neuroendocrine responses to endotoxin in human immunodeficiency virus-infected subjects. J Infect Dis 1999; 180: 106–15.PubMedCrossRefGoogle Scholar
  23. 23.
    DiPiro JT. Cytokibe networks with infection: microbacterial infections, leishmaniasis, human immunodeficiency virus infection, and sepsis. Pharmacotherapy 1997; 17: 205–23.PubMedGoogle Scholar
  24. 24.
    Spellberg B, Edwards JE. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis 2001; 32: 76–102.PubMedCrossRefGoogle Scholar
  25. 25.
    Schliep TC, Yarrish RL. Pneumocystis carinii pneumonia. Semin Respir Infect 1999; 14: 333–43.PubMedGoogle Scholar
  26. 26.
    Mansharamani NG, Garland R, Delaney D, et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: Comparison of HIV-associated cases to other immunocompromised states. Chest 2000; 118: 704–11.PubMedCrossRefGoogle Scholar
  27. 27.
    Bedos JP, Dumoulin JL, Gachot B, et al. Pneumocystis carinii pneumonia requiring intensive care management: survival and prognostic study in 110 patients with human immunodeficiency virus. Crit Care Med 1999; 27: 1109–15.PubMedCrossRefGoogle Scholar
  28. 28.
    Confalonieri M, Calderini E, Terraciano S, et al. Noninvasive ventilation for treating acute respiratory failure in AIDS patients with Pneumocystis carinii pneumonia. Intensive Care Med 2002; 28: 1233–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Kumar SD, Krieger BP. CD4 lymphocyte counts and mortality in AIDS patients requiring mechanical ventilator support due to Pneumocystis carinii pneumonia. Chest 1998; 113: 430–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Schneider RF. Bacterial pneumonia. Semin Respir Infect 1999; 14: 327–32.PubMedGoogle Scholar
  31. 31.
    Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11: 1731–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest 2000; 117: 1017–22.PubMedCrossRefGoogle Scholar
  33. 33.
    Schneider RF, Rosen MJ. Pneumococcal infections in HIV-infected adults. Semin Respir Infect 1999; 14: 237–42.PubMedGoogle Scholar
  34. 34.
    Harwell J, Brown RB. The drug-resistant pneumococcus: clinical relevance, therapy, and prevention. Chest 2000; 117: 530–41.PubMedCrossRefGoogle Scholar
  35. 35.
    Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program. Clin Infect Dis 2001; 32: S81–93.PubMedCrossRefGoogle Scholar
  36. 36.
    Meynard JL, Barbut F, Blum L, et al. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 22: 437–40.PubMedCrossRefGoogle Scholar
  37. 37.
    Feldman C, Glatthaar M, Morar R, et al. Bacteremic pneumococcal pneumonia in HIV seropositive and HIV seronegative adults. Chest 1999; 116: 107–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Turett GS, Blum S, Fazal BA, et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999; 29: 321–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Zahar JR, Azoulay E, Klement E, et al. Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure. Intensive Care Med 2001; 27: 513–20.PubMedCrossRefGoogle Scholar
  40. 40.
    Acosta BS, Grimsley EW. Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. South Med J 1999; 92: 421–3.PubMedCrossRefGoogle Scholar
  41. 41.
    Boswell DE, Styrt BA. Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors abstract 1284 ]. In Abstracts of the 39`h Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999: 496.Google Scholar
  42. 42.
    Sundar K, Saurez M, Banogon PE, et al. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med 1997; 25: 1425–30.PubMedCrossRefGoogle Scholar
  43. 43.
    Mokrycki MH, Harris C, May H, et al. Lactic acidosis associated with stavudine administration: a report of live cases. Clin Infect Dis 2000; 30: 198–200.CrossRefGoogle Scholar
  44. 44.
    Brinkman K, Ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735–44.PubMedCrossRefGoogle Scholar
  45. 45.
    Cortez KJ, Cotterio RA, Mileno MD, et al. Non-fatal nucleoside analogue-associated lactic acidosis in three HIV-infected patients [abstract 212]. In Program and Abstracts of the 37`h Annual Meeting of the Infectious Disease Society of America, Philadelphia, 1999: 76.Google Scholar
  46. 46.
    Luzzati R, Del Bravo P, Di Perrie G, et al. Riboflavin and severe lactic acidosis [letter]. Lancet 1999; 353: 901–2.PubMedCrossRefGoogle Scholar
  47. 47.
    Fouty B, Frerman F, Reyes R. Riboflavin to treat nucleoside analogue induced lactic acidosis [letter]. Lancet 1998; 352: 291–2.PubMedCrossRefGoogle Scholar
  48. 48.
    Chodock R, Mylonakis E, Shemin D, et al. Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis: Role of hemodialysis treatment. Nephrol Dial Transplant 1999; 14: 2484–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in a HIV patient: A case report. AIDS 1997; 11: 1294–6.Google Scholar
  50. 50.
    Schramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur J Anaesthesiol 1999; 16: 733–5.PubMedGoogle Scholar
  51. 51.
    Dutta SK, Ting CD, Lai LL. Study of prevalence, severity and etiological factors associated with acute pancreatitis in patients infected with human imunodeficiency virus. Am J Gastroenterol 1997; 92: 2044–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Guillermo Ortiz-Ruiz
  • Carlos Alvarez

There are no affiliations available

Personalised recommendations